

SUBJECT INDEX

A

Abdel-Latif, A. A., 86

Acetaminophen

cytochrome P-450 enzymes
and, 250

hepatotoxicity of, 170

toxic metabolites of, 12

Acetanilide

metabolism and distribution
of, 5

2-Acetylaminofluorene

embryonic bioactivation of,
176

embryotoxic effects of, 180

teratogenicity of, 169-70

Acetylcholine

coexistence with vasoactive
intestinal peptide, 95

ganglionic norepinephrine
and, 16

leukotrienes and, 126

Acquired immune deficiency

syndrome

azidothymidine and, 111

dialyzable leukocyte extract
therapy and, 502

Acrolein

embryotoxic effects of, 180

ACTH

hypersecretion of

reserpine and, 17

release of

benzodiazepines and, 309

Acyclovir

herpes simplex virus and,
111

Acyl-CoA:dihydroxyacetone

phosphate acyltransferase

hepatic peroxisome prolifera-
tion and, 148

Addiction

cocaine, 520

psychopharmacology of, 520-
22

Ader, J.-L., 354

Adipate ester plasticizers

hepatic peroxisome prolifera-
tion and, 147

Adipocytes

phospholipase C activation in,
91

Adrenal gland

benzodiazepine receptors in,
308-9

α_1 -Adrenergic receptors

inositol phospholipid metabo-
lism and, 85-87

Adriamycin

teratogenicity of, 175

Adult respiratory distress syn-
drome

leukotrienes and, 123

Aflatoxin

teratogenicity of, 175

Air pollutants

indoor

toxic effects of, 419-20

toxicology strategies for,
416-22

Air pollution

indoor, 415-16

causative agents of, 427-29

Airway smooth muscle

leukotrienes and, 125-27

Akhtar, R. A., 86

Albertini, R. J., 199

Aldosterone

production of

diazepam and, 309

synthesis and release of

atriopectin and, 25, 38-39

Aldrin epoxidation

cytochrome P-450 enzymes
and, 247

Alkanes

hepatic peroxisome prolifera-
tion and, 147

Alkanols

nail penetration by, 64

Allergic rhinitis

leukotrienes and, 134

Allison, J. H., 96

Alopecia totalis

dialyzable leukocyte extract
therapy and, 495

glucocorticoids and, 66

Altmeier, P., 59

Alzheimer's disease

dialyzable leukocyte extract
therapy and, 497-98

glutamate receptors and, 457-
58

glutamate transport in, 389

N-methyl-D-aspartate recep-
tors and, 89

Ames, B. N., 196

4-Aminobiphenyl

environmental tobacco smoke
and, 426

2-Amino-4-phosphonobutyrate
receptors, 377-79

Aminophosphonobutyric acid
long-term potentiation of syn-
aptic transmission and,
89

2-Amino-5-phosphonovalerate
excitatory amino acids and,
88

Aminopyrine

hepatic demethylation of, 9

metabolism and distribution
of, 5

Amphetamine

hepatic enzyme system and,
9-10

Amyotrophic lateral sclerosis

dialyzable leukocyte extract
therapy and, 498

Anderson, K. A., 388

Androgens

conversion to estrogens, 253

teratogenicity of, 166

Androstenedione

cytochrome P-450 enzymes
and, 247

Angiotensin

exogenous

atriopectin and, 26

phosphoinositide hydrolysis
and, 89

Angiotensin II

atriopectin-induced natriuresis
and, 36

plasma atriopectin levels and,
31

Aniline

cytochrome P-450 enzymes
and, 250

Anisoylated plasminogen-

streptokinase activator com-
plex

pharmacology of, 331-32

Anthrakin

psoriasis and, 62

skin disease and, 59

Antiarhythmic

bile acid-binding resins and,
271

Antibacterials

skin disease and, 59

Antibiotics

skin disease and, 59

Anticholinergics

skin disease and, 59

Anticoagulants

bile acid-binding resins and,
271

teratogenicity of, 166

Anticonvulsants

teratogenicity of, 166

Antidepressants

inositol lipid metabolism and,
83

- Antifungals
 nail penetration by, 64
 penetration enhancers and, 60-61
 skin disease and, 59
 tinea capitis and, 66
 Antihistamines
 teratogenicity of, 175
 Antihypertensives
 bile acid-binding resins and, 271
 nicotinic acid and, 275
 Antiparasitics
 skin disease and, 59
 Antipyrene
 metabolism and distribution of, 5
 Antiseptics
 skin disease and, 59
 Antivirals, 111-20
 design of, 112-16
 problems in, 116-19
 prospects for, 119-20
 Anxiety
 N-methyl-D-aspartate receptors and, 454-55
 Aprotinin
 proatriopectin-processing enzyme and, 33
 Arachidonic acid
 leukotrienes and, 123-24
 phospholipase A₂ and, 123
 second messengers and, 74
 Arbeit, L. A., 354
 Arousal
 N-methyl-D-aspartate receptors and, 453
 Arteriosclerotic cardiovascular disease
 dyslipidemias and, 265
 Ascher, P., 370, 372
 Ascorbate
 embryonic defense and, 181-82
 Ashby, R., 179
 Aspartate
 2-amino-5-phosphonovalerate and, 88
 phosphoinositide breakdown and, 87
 Asthma
 leukotrienes and, 123
 slow-reacting substance of anaphylaxis and, 133
 Astrocytes
 glutamate-binding sites on, 388
 Atabrine
 tissue distribution of
 dosing regimens and, 4
 Atenolol
 atriopectin release and, 31
 Atrial fibrillation
 nicotinic acid and, 275
 Atrial natriuretic factor, 23
 Atrial natriuretic peptide, 23
 Atrial peptides, 23-45
 Atrial stretch receptors
 heart rate modulation and, 31
 Atriopectin
 biological activity of
 suppression of, 25
 biosynthesis and storage of, 26-28
 brain and, 26
 cardiac biosynthesis of, 23-24
 cardiovascular effects of, 37-38
 central nervous system and, 39-42
 developmental regulation of, 30
 expression in cardiac ventricle, 42-44
 gene structure and organization of, 28-29
 hormonal interactions of, 38-39
 metabolism of, 33-34
 receptors for, 25, 34-35
 regulatory sequences of, 29-30
 release of, 24-25, 30-33
 renal actions of, 36-37
 Atropine
 atriopectin secretion and, 31
 metabolism and distribution of, 5
 muscarinic cholinergic receptors and, 83
 side effects of, 136
 Austen, K. F., 134
 Autism
 dialyzable leukocyte extract therapy and, 497-98
 Axelrod, J., 4, 5, 9, 10
 Azarnoff, D. L., 147
 Azidothymidine
 acquired immune deficiency syndrome and, 111
B
 Bainbridge reflex
 atrial stretch receptors and, 31
 Balduini, W., 85
 Bang, N. U., 323
 Batrachotoxin
 inositol phosphate release and, 92
 Batty, I., 97
 Beaune, P., 248, 251
 Becker, B. A., 167
 Becker, C. M., 156
 Behcet's syndrome
 dialyzable leukocyte extract therapy and, 493-95
 Benzamide
 proatriopectin-processing enzyme and, 33
 Benzo(a)pyrene
 embryonic bioactivation of, 176
 environmental tobacco smoke and, 426
 teratogenicity of, 175
 Benzodiazepine receptors
 peripheral, 307-18
 localization and regulation of, 308-11
 mitochondria and, 311
 molecular properties of, 315-18
 porphyrins and, 312-13
 Benzodiazepines
 anxiolytic action of, 16
 peripheral
 biological effects of, 313-15
 Benzoyl benzoate
 skin disease and, 59
 Benzoyl peroxide
 skin disease and, 59
 Benzphetamine N-demethylation
 cytochrome P-450 enzymes and, 247
 Berliner, R., 4, 5
 Bernard, W., 146
 Berridge, M. J., 78, 80, 81, 96
 Betamethasone dipropionate
 vehicles for, 56
 Bisgaard, H., 134, 135
 Blaine, E. H., 23
 Blanke, H., 324
 Blumgart, H. L., 324
 Bombesin
 phosphoinositide hydrolysis and, 89
 Bonner, T. I., 83
 Bradykinin
 phosphoinositide hydrolysis and, 89
 Brain
 atriopectin and, 26
 benzodiazepine receptors in, 308-11
 Brain peptides, 521-22
 Braun, A. G., 172, 174
 Bretylum
 heart norepinephrine content and, 14
 Brewer, G., 385
 Bridges, R. J., 365
 Brodie, B. B., 1-18
 Brodie, S., 2, 8

- Bromobenzene
 - toxic metabolites of, 12
- Bronchitis
 - chronic
 - leukotrienes and, 123
- Bronchoconstriction
 - leukotrienes and, 133-34
- Bronfman, M., 156
- Brown, D. A., 89
- Brown, L. P., 177
- Buckner, C., 127
- Bukowski, R. M., 497
- Burch, G. E., 64
- Burns, J., 4
- C
- Caffeine
 - teratogenicity of, 175
- Calcium
 - intracellular
 - atriopectin release and, 32
 - release of
 - inositol phosphates and, 77-79
- Calcium channel agonist BAY k8644
 - atriopectin release and, 32
- Calcium ionophore A23187
 - atriopectin release and, 32
- Calcium-mobilizing receptors
 - phosphoinositide response and, 92-94
- Campbell, J. B., 407
- Cancer chemotherapeutic agents
 - teratogenicity of, 166
- Candidiasis
 - dialyzable leukocyte extract therapy and, 489-90
- Carbamazepine
 - anticonvulsant actions of
 - benzodiazepine receptors and, 311
- Carbon tetrachloride
 - hepatic toxicity of
 - phenobarbital and, 12
- Carcinogenesis
 - cytochrome P-450 enzymes and, 245
- Cardiac arrhythmias
 - nicotinic acid and, 275
 - probulcol and, 273
- Cardiac ventricle
 - atriopectin expression in, 42-44
- Cardionatriin, 23
- Cardiovascular disease
 - arteriosclerotic
 - dyslipidemias and, 265
- Cardiovascular system
 - atriopectin and, 37-38
- Camitine acetyltransferase
 - hepatic peroxisome proliferation and, 148
- Camitine octanoyltransferase
 - hepatic peroxisome proliferation and, 148
- β -Carotene
 - embryonic defense and, 181-82
- Catalase
 - embryonic defense and, 181-82
 - hepatic peroxisomes and, 146
- Cataracts
 - lovastatin and, 279
- Catecholamines
 - depletion of
 - reserpine syndrome and, 13
 - thermoregulation and, 17
- Central nervous system
 - atriopectin secretion and, 32
 - neuronal projections in
 - chemical coding of, 293
- Chemical genotoxicity, 189-204
- Chemical teratogenesis, 165-82
- Chen, S. T., 253, 254, 409
- Chloramphenicol acetyltransferase
 - atriopectin gene and, 29
- Chlorhexadine
 - skin disease and, 59
- Chloroquine
 - phosphoinositide breakdown and, 91
- Choi, D. W., 386
- Cholecystokinin
 - phosphoinositide hydrolysis and, 89
- Cholesterol
 - primary dyslipidemias and, 265
- Cholestyramine
 - primary dyslipidemias and, 268-70
- Chromosome mutation, 200-3
- Chronic discoid lupus erythematosus
 - dialyzable leukocyte extract therapy and, 495-96
- Chronic familial mucocutaneous candidiasis
 - dialyzable leukocyte extract therapy and, 489-90
- Chronic hyperfatigability-cognitive dysfunction syndrome
 - dialyzable leukocyte extract therapy and, 498-99
- Chuang, D.-M., 71, 84, 93, 95
- Ciprofibrate
 - hepatic peroxisome proliferation and, 149
- Claxton, L. D., 420
- Clayman, M. D., 323
- Clofibrate
 - hepatic peroxisome proliferation and, 148, 149, 151
 - primary dyslipidemias and, 273
- Clonazepam
 - binding sites of, 308
- Coal tar
 - skin disease and, 59
- Cocaine addiction, 520
- Colestipol
 - primary dyslipidemias and, 268
- Collen, D., 332, 333
- Congestive heart failure
 - atriopectin and, 37, 44
- Conn, P. J., 82
- Convulsions
 - benzodiazepines and, 314
 - N-methyl-D-aspartate receptors and, 454
- Coproporphyrin
 - benzodiazepine receptors and, 313
- Cortisol
 - cytochrome P-450 enzymes and, 247
- Costa, E., 1, 88
- Costa, M., 289, 292
- Cotinine
 - detection of, 425-26
- Cotman, C. W., 365
- Creutzfeld-Jacob disease
 - dialyzable leukocyte extract therapy and, 498
- Crews, F. T., 91
- Critchley, M., 407
- Crouch, M. F., 91
- Cryptosporidia
 - dialyzable leukocyte extract therapy and, 502
- Curtis, D. R., 367, 386
- Cutaneous leishmaniasis
 - dialyzable leukocyte extract therapy and, 492-93
- Cyclic nucleotides
 - kinin responses and, 352
- Cyclophosphamide
 - teratogenicity of, 167-69
- Cyclosporin hydroxylation
 - cytochrome P-450 enzymes and, 247
- Cystic fibrosis
 - leukotrienes and, 123
- Cytochrome P-450 enzymes, 241-56
- Cytochrome P-452
 - induction of, 149-50

D

- Daly, J. W., 92
 Danyasz, W., 441
 Davidson, A. B., 134
 Dawson, A. P., 78
 de Duve, C., 146
 DEHP
 hepatic peroxisome proliferation and, 149
 hepatomegaly and, 150
 Dehydroepiandrosterone 3-sulfate
 cytochrome P-450 enzymes and, 247
 Deltamethrin
 convulsions and, 314
 Dementia
 multiple infarct, 411
 Depression
 desmethylinipramine and, 13
 Desipramine
 cortical serotonin receptor response and, 83
 Desmethylinipramine
 depression and, 13
 Deuteroporphyrin IX
 benzodiazepine receptors and, 313
 DeWood, M. A., 324
 Dexamethasone
 atriopectin gene expression and, 29
 Diabetes mellitus
 kallikrein-kinin system and, 355-56
 lipoprotein abnormalities and, 266
 Diacylglycerol
 generation of, 72-76
 mode of action of, 76-79
 protein kinase C and, 32, 76-77
 generation of, 72-76
 Dialyzable leukocyte extract, 477-78
 antigen-specific responses to, 485-86
 choice of donor for, 480-81
 clinical response to laboratory monitoring of, 485
 fungal diseases and, 489-90
 immunotherapy with, 479-89
 interactive T cells and, 486-87
 in vitro effects of, 487-89
 malignant diseases and, 496-97
 mycobacterial diseases and, 490-92
 neurologic diseases and, 497-99
 parasitic infections and, 492-93
 potency of
 in vitro determination of, 483-85
 preparation of, 481-83
 side effects of, 479-80
 therapeutic failures with, 499
 viral infections and, 493-96
 Diazepam
 binding sites of, 307-8
 1,1-Dichloroethane
 carcinogenicity of, 433
 Dichloroflavan
 picornavirus uncoating and, 113
 Dicumarol
 duration of action of
 plasma protein binding and, 11
 metabolism and distribution of, 5
 Diethylstilbestrol
 embryonic bioactivation of, 176
 teratogenicity of, 166, 175
 Digitalis
 bile acid-binding resins and, 271
 1,4-Dihydropyridines
 cytochrome P-450 enzymes and, 247
 5,7-Dihydroxytryptamine
 cortical serotonin receptor response and, 83
 Dillon-Carter, O., 93
 Dimethylacetamide
 percutaneous drug penetration and, 62
 Dimethylsulfoxide
 percutaneous drug penetration and, 62
 Disopropyl fluorophosphate
 proatriopectin-processing enzyme and, 33
 Disoxaril
 picornavirus uncoating and, 113-14
 Diuretics
 bile acid-binding resins and, 271
 thiazide
 secondary dyslipidemias and, 266
 DNA
 chemicals damaging, 190-96
 Docosahexaenoic acid
 dyslipidemias and, 281-82
 Dopamine
 depletion of
 reserpine syndrome and, 13
 kallikrein gene expression and, 348
 Drazen, J. M., 134
 Drinking behavior
 atriopectin and, 42
 Drug-metabolizing enzyme system
 neonates and, 10
 smooth endoplasmic reticulum and, 9
 Drug problem, 518-19
 Drugs
 elimination of
 genetic variation in, 10-11
 embryonic bioactivation of, 175-78
 metabolism and disposition of, 8-12
 metabolites of
 clinical utility of, 11
 percutaneous absorption of, 55-66
 drug vehicles and, 55-59
 nails and, 64-65
 penetration enhancers and, 59-61
 regional differences in, 65-66
 stratum corneum and, 61-63
 sports performance and, 517-18
 tissue distribution of
 dosing regimens and, 4-5
 topical
 penetration enhancers and, 59-61
 Drummond, A. H., 96
 Duckert, F., 330
 Dujovne, C. A., 265
 Dumas, K. J., 59
 Dysbetalipoproteinemia
 arteriosclerotic cardiovascular disease and, 266
 Dyslipidemias, 265-84
 agents affecting, 280-82
 combined drug therapy for, 282-83
 primary, 265-66
 drugs for, 268-80
 secondary, 266
 E
 Eacho, P. I., 155
 Eatough, D. J., 424
 Econazole
 nail penetration by, 64
 Eicosapentaenoic acid
 dyslipidemias and, 281-82
 Elcombe, C. R., 145
 Embolic stroke, 410-11
 Embryo
 drug bioactivation in, 175-78

- reactive metabolites and, 178-82
 β -Endorphin, 521
 Endoneurine
 benzodiazepine receptors and, 312
 Enkephalins, 521
 Enteroviruses
 serotypes of, 113
 Ephedrine
 hepatic enzyme system and, 9-10
 inositol phosphate release and, 85
 Epidermal dysplasia
 dialyzable leukocyte extract therapy and, 495-96
 Epinephrine
 atrioventricular secretion and, 32
 inositol phosphate release and, 85
 Epoxide hydrolases
 embryonic defense and, 181-82
 Erythromycin N-demethylation
 cytochrome P-450 enzymes and, 247
 Estradiol-17 β
 cytochrome P-450 enzymes and, 247
 teratogenicity of, 175
 Estrogens
 androgen conversion to, 253
 dyslipidemias and, 280-81
 kallikrein gene expression and, 348
 Ethanol
 cytochrome P-450 enzymes and, 250
 teratogenicity of, 166, 175
 17 α -Ethinylestradiol
 cytochrome P-450 enzymes and, 247
 Evans, C. T., 253
 Evans, J. P., 408
 Excitatory amino acid receptors, 87-89, 365-91
 cell growth and, 385
 classification of, 367-81
 developmental plasticity of, 382-84
 excitotoxic actions of, 386-88
 long-term potentiation of, 384-85
 Excitatory amino acids
 transport sites of, 388-89
 Exton, J. H., 90

F
 Farsang, C., 524
 Fatty acid oxidation
 peroxisome proliferators and, 156
 Fenofibrate
 hepatic peroxisome proliferation and, 151
 Ferritin
 embryonic defense and, 182
 Fibrates
 primary dyslipidemias and, 273-74
 Fibrinolytic enzyme system
 biochemistry of, 325-29
 Fijken, D. C., 332
 Fisher, S. K., 84
 Fish oils
 dyslipidemias and, 281-82
 Flatman, J. A., 371
 Fleisch, J. H., 123
 Flint, O. P., 177
 Flunitrazepam
 molecular properties of, 315-16
 Fluocinolone acetonide
 concentration of
 biologic potency and, 59
 Fog, T., 499
 Fowler, C. J., 86
 Foxworthy, P. S., 155
 Freud, S., 520
 Friedman, M. M., 3
 Fudenberg, H. H., 475
 Fungal diseases
 dialyzable leukocyte extract therapy and, 489-90
 Furazolidone
 teratogenicity of, 171
 Furness, J. B., 289, 292
 Furosemide
 extracellular fluid volume and, 37

G
 GABA
 benzodiazepine receptors and, 312
 GABA receptor
 homeotypic modulation of, 17
 Garbarg, M., 95
 Gavras, H., 354
 Gemfibrozil
 hepatic peroxisome proliferation and, 151
 lovastatin and, 279
 primary dyslipidemias and, 273-74
 Gene mutation, 196-200
 Genotoxicity, 189-204
 interpretation of, 203-4
 Gibbins, I. L., 289
 Gibson, J. E., 167
 Giles, H., 224
 Gill, D. L., 78
 Gillette, J., 12
 Glaser, U., 433
 Glomerular filtration rate
 atrioventricular-induced natriuresis and, 36
 Glucocorticoids
 alopecia totalis and, 66
 atrioventricular gene expression and, 29
 clinical potency of
 vasoconstrictor bioassay and, 56
 kallikrein gene expression and, 348
 plasma levels of
 benzodiazepines and, 309
 skin disease and, 59
 topical
 psoriasis and, 65-66
 stratum corneum and, 62
 vehicles for, 55-59
 Glucose tolerance
 nicotinic acid and, 275
 Glutamate
 2-amino-5-phosphonovaleate and, 88
 neurotoxicity of, 459-60
 phosphoinositide breakdown and, 87
 Glutamate receptors
 ionotropic, 442-43
 learning and memory and, 455-57
 metabotropic, 443-44
 modulation of, 441-61
 neurodegenerative diseases and, 457-60
 psychoses and, 460-61
 signal transduction at, 442-44
 Glutathione-S-transferase
 benzodiazepine receptors and, 316-17
 leukotrienes and, 127
 Glycine
 N-methyl-D-aspartate receptors and, 446
 Gomperts, B. D., 90
 Gonzales, R. A., 91
 Gonzalez, F. J., 243, 244, 247
 Gordon, G. B., 174, 174
 Greenberger, P. A., 135
 Greenwald, J. E., 23
 Growth hormone
 release of
 benzodiazepines and, 309
 GTP
 calcium release and, 78
 GTP binding protein
 phospholipase C-coupled receptors and, 90-92
 Guanethidine
 heart norepinephrine content and, 14

- Guengerich, F. P., 241
- H**
- Hahn, R. A., 135
- Hales, B. F., 167, 168, 174, 179
- Halushka, P. V., 213
- Harris, R. A., 156
- Harris, W. S., 265
- Hatcher, W. H., 2
- Heacock, A. M., 84
- Heart rate
atrial stretch receptors and, 31
- Heme
benzodiazepine receptors and, 313
- Hemoglobin
atriopeptin and, 37
- Heparin
exogenous
atriopeptin suppression and, 25
- Hepatomegaly
peroxisome proliferators and, 150-51
- Herpes simplex
dialyzable leukocyte extract therapy and, 493
- Herpes simplex virus
acyclovir and, 111
- Herxheimer, H., 133
- Hess, R., 147
- Hess, S. M., 14
- Hexamethonium
muscarinic cholinergic receptors and, 83
- Higashida, H., 89
- High-density lipoprotein cholesterol
relative hypercholesterolemia and, 266
- Higuchi, T., 56
- Hinson, J., 12
- Histamine
leukotrienes and, 126
- HMG-CoA reductase inhibitors
primary dyslipidemias and, 278-79
- Hobin, L., 72
- Hokin, M., 72
- Holroyde, M. C., 133
- Homeostasis
hypothalamic-pituitary-adrenal axis and, 17-18
- Huang, K. P., 77
- Human immunodeficiency virus, 111
- Huntington's disease
glutamate receptors and, 458
- N-methyl-D-aspartate-like lesions in, 387
- Hydrocortisone
concentration of
biologic potency and, 58-59
- 5-Hydroxyoxyicosatetraenoic acid
leukotrienes and, 124
- Hydroxy acids
skin disease and, 59
- 5-Hydroxyindole acetic acid
urinary content of
serotonin and, 12
- 17-Hydroxyprogesterone
cytochrome P-450 enzymes and, 254
- Hypercholesterolemia
arteriosclerotic cardiovascular disease and, 265
- gemfibrozil and, 274
- hypertriglyceridemia and, 266
- ion exchange resins and, 270
- lovastatin and, 278-79
- neomycin and, 280
- nicotinic acid and, 275
- probucol and, 272
- Hyperlipidemia
fish oils and, 282
- nicotinic acid and, 275
- probucol and, 272
- Hypertension
atriopeptin and, 38
- kallikrein-kinin system and, 354-55
- Hypertriglyceridemia
gemfibrozil and, 273-74
- hypercholesterolemia and, 266
- Hyperuricemia
nicotinic acid and, 275
- Hypervolemia
atriopeptin secretion and, 31
- Hypoglycemia
glutamate receptors and, 459
- Hypolipidemias
cytochrome P-452 induction and, 150
- hepatic peroxisome proliferation and, 147
- hepatomegaly and, 150
- Hypothalamico-pituitary-adrenal axis
homeostasis and, 17-18
- Hypothyroidism
lipoprotein abnormalities and, 266
- Hypoxia
atriopeptin release and, 32
- I**
- Ibotenic acid
inositol phosphate formation and, 87
- Illes, P., 524
- Imipramine
antidepressant action of
serotonin and, 13
- inositol lipid metabolism and, 83
- Immune system
leukotrienes and, 123
- Immunosuppressives
lovastatin and, 279
- Indomethacin
leukotriene response and, 126
- Inflammatory bowel disease
leukotrienes and, 123
- Inositol phosphates
generation of, 72-76
- metabolism of, 74-76
- mode of action of, 76-79
- Inositol triphosphate
intracellular calcium release and, 32
- Insulin
dyslipidemias and, 280
- kallikrein gene expression and, 348
- Ion exchange resins
primary dyslipidemias and, 268-72
- Ipindol
inositol lipid metabolism and, 83
- Iproniazid
excitatory action of, 13
- Irvine, R. F., 76, 79
- Ischemia
bilateral hemispheric, 405-6
- focal, 407-10
- glutamate receptors and, 458-59
- multiple, 410-11
- unilateral hemispheric, 406-7
- Isobutylmethylxanthine
leukotriene receptors and, 130
- J**
- Jafferji, S. S., 81
- Jain, R., 174
- Jaiswal, A. K., 252
- Jancso, G., 387
- Janowsky, A., 82, 86
- Joffy, A., 475
- Johnson, A. J., 328
- Johnson, B., 517
- Johnson, J. W., 370
- Jollow, D., 12
- Juchau, M. R., 165
- K**
- Kagimoto, M., 255
- Kainate receptor
properties of, 375-76

- synaptic transmission at, 376-77
- Kalant, O. J., 520
- Kallikreins, 343-56
molecular genetics and structure of, 344-49
roles in disease, 353-56
- Kamataki, T., 245
- Kanigel, R., 8
- Kaplan, J., 519
- Karczmar, A. G., 1
- Karpiak, S. E., 403
- Katz, M., 55
- Kellis, J. T. Jr., 253
- Kendall, D. A., 82, 86
- Ketamine
N-methyl-D-aspartate receptor and, 372
- Ketanserin
serotonin inhibition and, 81
- Kidney
atriopectin and, 36-37
benzodiazepine receptors in, 310
- Kidney disease
lipoprotein abnormalities and, 266
- Kininses
kinin catabolism and, 353
- Kinin receptors
properties of, 350-52
- Kinins, 343-56
cellular and tissue responses to, 349-53
molecular genetics and structure of, 344-49
roles in disease, 353-56
- Kitada, M., 245
- Knight, A. G., 64
- Krell, R. D., 127
- Kumar, N. S., 147
- L
- Lader, M., 520
- La Du, B., 9
- Lalwani, N. D., 152
- Laniado-Schwartzman, M., 251
- Lapetina, E. G., 91
- Lasker, J. M., 248, 250
- Lawrence, H. S., 475, 476
- Lazarow, P. B., 149
- Leake, C., 523
- Learning
excitatory amino acid receptors and, 89
glutamate receptors and, 455-57
- Learning process
- Leff, P., 224
- Leishmaniasis
- dialyzable leukocyte extract therapy and, 492-93
- Lepromatous leprosy
dialyzable leukocyte extract therapy and, 490-92
- Lesser, P. G., 490
- Leukemic cells
phospholipase C activation in, 91
- Leukotriene receptor antagonists, 123-38
characteristics of, 129-33
pharmacologic evaluation of, 135-37
structural types of, 127-29
- Leukotriene receptors, 226-29
purification and biophysical properties of, 228-29
radioligand-binding studies of, 227-28
second messenger systems for, 226-27
- Leukotrienes
airway smooth muscle and, 125-27
formation of, 123-24
human pharmacology of, 133-35
pharmacologic effects of, 123
- Leupeptin
proatriopectin-processing enzyme and, 33
- Levinthal, C. F., 521
- Lewtas, J., 415
- Lieberthal, W., 355
- Lithium
phosphoinositide metabolism and, 96-97
- Litosch, L., 90
- Liver
drug-metabolizing enzyme system of, 9
peroxisome proliferation in, 145-57
- Lock, E. A., 145
- Lodge, D., 372
- Loewi, O., 3
- Louie, E., 502
- Lovastatin
primary dyslipidemias and, 278-79
- Low-density lipoprotein
cholesterol
arteriosclerotic cardiovascular disease and, 265-66
- Lübbert, H., 82
- Lucas, D. R., 386
- Lundberg, J. M., 292
- Luteinizing hormone
release of
atriopectin and, 26
benzodiazepines and, 309
- Lymphocytes
benzodiazepines and, 315
- M
- MacDonald, B. R., 135
- MacDonald, J. F., 371, 375
- Macrophages
benzodiazepines and, 315
- Magnesium
N-methyl-D-aspartate receptors and, 444-45
- Maier, H., 520
- Mais, D. E., 213
- Majerus, P. W., 76
- Malaria
atabrine therapy and, 4
- Malignant diseases
dialyzable leukocyte extract therapy and, 496
- Malthion
skin disease and, 59
- Manic depression
lithium and, 96
- Manson, J. M., 176
- Margolius, H. S., 343
- Marone, G., 135
- Marshall, K., 4
- Mat cells
phospholipase C activation in, 91
- Matsuo, H., 26, 39
- Matteson, K. J., 254
- Mayer, M. L., 372
- Mayeux, P. R., 213
- McCarty, W. R., 328
- McKinaly, M. A., 111
- Mecamylamine
muscarinic cholinergic receptors and, 83
- Melanogenesis
benzodiazepines and, 314
- Melanoma
dialyzable leukocyte extract therapy and, 496
- Mellow, A., 82
- Memory
excitatory amino acid receptors and, 89
glutamate receptors and, 455-57
- Mendelson, C. R., 253
- Mengoviruses
structure of, 113
- Mercuric chloride
embryotoxic effects of, 180
- Mesoporphyrin IX
benzodiazepine receptors and, 313
- Metastases
dialyzable leukocyte extract therapy and, 497

532 SUBJECT INDEX

- Methadone, 523
 Methisazone
 pox virus replication and, 111-112
 Methoxamine
 atriopectin-induced natriuresis and, 36
 inositol phosphate release and, 85
 Methoxyethanol
 teratogenicity of, 175
 Methylclophenapate
 hepatic peroxisome proliferation and, 149
 N-Methyl-D-aspartate-glycine receptor, 370-71
 N-Methyl-D-aspartate receptor, 87-89
 Alzheimer's disease and, 89
 developmental plasticity of, 382-84
 excitotoxicity of, 387
 heterogeneity of, 374-75
 ion channel of, 371-72
 blockade of, 372-73
 learning and memory and, 456-57
 long-term potentiation of, 384-85
 modulation of
 behavioral expression of, 452-55
 modulators of, 444-46
 recognition sites for, 446-51
 recognition site of, 370
 N-Methyl-D-aspartate receptor-ionophore complex, 368-75
 Meyer, T., 78
 Miadonna, A., 134
 Mianserin
 cortical serotonin receptor response and, 83
 Michell, R. H., 81
 Michener, M. L., 23
 Miller, J., 475
 Mineralocorticoids
 kallikrein gene expression and, 348
 Minneman, K. P., 86
 Mirkes, P. E., 168
 Misonidazole
 teratogenicity of, 171
 Mitchell, A. M., 145
 Mitchell, J., 12
 Mitochondria
 benzodiazepine receptors and, 311
 Mody, I., 375
 Molhave, L., 430, 432, 433
 Molowa, D. T., 246
 Monaghan, D. T., 87, 365
 Monoamine oxidase inhibitors
 action of
 norepinephrine levels and, 13
 Monocytes
 benzodiazepines and, 315
 Monooxygenases
 cytochrome P-450 mediated, 9
 Moor, R. M., 79
 Morinelli, T. A., 213
 Morris, J. L., 289
 Motivation
 N-methyl-D-aspartate receptors and, 453
 mRNA
 atriopectin
 expression of, 26-27
 Muller, H. J., 198
 Muscarinic cholinergic receptors
 atropine and, 136
 phospholipase C and, 83-85
 Mutagenesis
 chemical, 196-200
 Muto, N., 253
 Myasthenia gravis
 dialyzable leukocyte extract therapy and, 499
 Mycobacterial diseases
 dialyzable leukocyte extract therapy and, 490-92
 Myocardial infarction
 pathophysiology of, 324-25
 thrombolytic therapy in, 323-36
 Myocardial ischemia
 leukotrienes and, 123
 N
 Nadelmann, E. A., 518
 NADPH
 drug-metabolizing enzyme system and, 9
 Nahorski, S. R., 82, 85, 97
 Nails
 drug penetration of, 64-65
 Nakahashi, Y., 355
 Nakaki, T., 81
 Nalorphine, 523
 Natriuresis
 atriopectin-induced, 36-37
 Nebert, D. W., 176, 177
 Needleman, P., 23
 Neel, J. V., 200
 Neomycin
 phosphoinositide breakdown and, 91
 primary dyslipidemias and, 279-80
 Neurohybrid NCB-20 cells
 phospholipase C activation in, 91
 Neurologic diseases
 dialyzable leukocyte extract therapy and, 497-99
 Neurons
 chemically coded, 292-94
 Neurotensin
 phosphoinositide hydrolysis and, 89
 Neurotransmitters
 actions of
 diversity of, 296-300
 colocalization of, 289-301
 corelease of, 294-96
 Neutrophils
 phospholipase C activation in, 91
 Newall, D. R., 174
 Newhouse, J. P., 386
 Nicoletti, F., 86, 87
 Nicotinamide
 benzodiazepine receptors and, 312
 Nicotine
 major metabolite of, 425-26
 Nicotinic acid
 lovastatin and, 279
 primary dyslipidemias and, 274-78
 Nifedipine
 cytochrome P-450 enzymes and, 247
 Nifuroxime
 teratogenicity of, 171
 Niridazole
 teratogenicity of, 170-71
 Nishizuka, Y., 76, 77, 94
 Nitrofurantoin
 teratogenicity of, 171
 Nitrofurazone
 teratogenicity of, 171
 Nitroheterocycles
 teratogenicity of, 170-72
 2-Nitroimidazole
 teratogenicity of, 171
 Nitrosamines
 environmental tobacco smoke and, 426
 Norepinephrine
 atriopectin secretion and, 32
 depletion of
 reserpine syndrome and, 13
 ganglionic
 acetylcholine and, 16
 heart content of
 adrenergic blockers and, 14
 inositol phosphate release and, 85
 leukotrienes and, 126
 monoamine oxidase inhibitors and, 13

- Norethindrone acetate
dyslipidemias and, 281
- Nowak, L., 372
- O**
- Obesity
lipoprotein abnormalities and, 266
- O'Brien, M. D., 408
- Olney, J. W., 386, 388
- Onychomycosis, 64
- Opiate receptors, 522-23
- Opioid peptides
regulatory role of, 524
- Opiopeptins, 521-22
- Oral contraceptives
dyslipidemias and, 280-81
- Organomercurials
teratogenicity of, 166
- Osteosarcoma
dialyzable leukocyte extract
therapy and, 496-97
- Ostrenga, J., 55
- Oxiconazole
nail penetration by, 64
- Oxymetazoline
inositol phosphate release
and, 85
- Oxyphenylbutazone
biotransformation of phenyl-
butazone to, 11
- P**
- Painter, R. B., 195
- Paraquat
teratogenicity of, 175
- Parasitic infections
dialyzable leukocyte extract
therapy and, 492-93
- Parvoviruses
structure of, 113
- Pasternak, G. W., 522, 523
- Pelkonen, P., 251
- Pemphigus vegetans
dialyzable leukocyte extract
therapy and, 495-96
- Pentyleneetetrazole
convulsions and, 314
- Pepeu, G., 95
- Peptidergic receptors
phosphoinositide hydrolysis
and, 89-90
- Peptides
phosphoinositide hydrolysis
and, 89
See also specific type
- Perchloroethylene
hepatic peroxisome prolifera-
tion and, 147
- Peripheral nervous system
atriopectin secretion and, 32
- Permethrin
convulsions and, 314
- Peroxidases
embryonic defense and, 181-
82
- Peroxisomal enzymes
induction of, 148-49
- Peroxisomes, 146-47
biogenesis of, 149
proliferation of, 147-51
induction of, 151-57
- Pertussis toxin
phospholipase C activation
and, 91
- Peterson, J. N., 408
- Phenacetin
metabolism and distribution
of, 5
- Phencyclidine
N-methyl-D-aspartate receptor
and, 372-73, 445-46
- Phenobarbital
drug elimination rates and, 11
liver toxicity of carbon tet-
rachloride and, 12
- Phenoxybenzamine
inositol lipid hydrolysis and,
85
- Phentolamine
atriopectin secretion and, 31
- Phenylbutazone
biotransformation to ox-
yphenylbutazone, 11
duration of action of
plasma protein binding and,
11
metabolism and distribution
of, 5
- Phenylephrine
inositol phosphate release
and, 85
plasma atriopectin levels and,
31
- Phenytion
teratogenicity of, 175
- Phillips, I. R., 252
- Phorbol esters
phospholipase C-coupled re-
ceptors and, 94
protein kinase C and, 76
- Phosphatidylethanolamine
benzodiazepine receptors and,
316
- Phosphatidylinositol system
atriopectin release and, 32
- Phosphoinositide-coupled recep-
tors, 71-99
- Phosphoinositides
hydrolysis of, 72-73
- Phospholipase A₂
arachidonic acid and, 123
- Phospholipase C
 α_1 -adrenergic receptors and,
85-87
excitatory amino acid recep-
tors and, 87-89
muscarinic cholinergic recep-
tors and, 83-85
phosphoinositide hydrolysis
and, 73-74
serotonergic receptors and,
81-83
- Phospholipase C-coupled recep-
tors
characteristics of, 80-90
effectors and, 94-96
regulation of, 90-97
- Phthalate ester plasticizers
hepatic peroxisome prolifera-
tion and, 147
- Physostigmine
thermoregulation and,
17
- Picornaviruses
replication of
compounds inhibiting, 113-
16
- Pirenzepine
muscarinic cholinergic recep-
tors and, 83-84
- Plasmin
fibrinolytic enzyme system
and, 325-29
- Plasminogen
fibrinolytic enzyme system
and, 325-29
- Platelets
phospholipase C activation in,
91
- Polioviruses
structure of, 113
- Porcine brain natriuretic peptide,
26, 39-40
- Porphyryns
benzodiazepine receptors and,
312-13
- Postural hypotension
nicotinic acid and, 275
- Potassium channel
phosphoinositide mechanism
and, 90
- Potter, B., 12
- Poulsen, B. J., 55
- Pox viruses
methisazone and, 111-12
- Prazosin
inositol phosphate release
and, 85
- Probuco
primary dyslipidemias and,
272-73
- Procainamide

- metabolism and distribution
 - of, 5
- Procaine
 - metabolism and distribution
 - of, 5
- Procarbazine
 - teratogenicity of, 175
- Progesterone
 - cytochrome P-450 enzymes
 - and, 247
- Prolactin
 - release of
 - benzodiazepines and, 309
- Propranolol
 - atriopectin secretion and,
 - 31
- Propylene glycol
 - drug vehicles and, 55-56
- Prostacyclin receptors, 217-21
 - purification of, 221
 - radioligand-binding studies of,
 - 218-20
 - second messenger systems
 - for, 217-18
 - subtypes of, 220
- Prostaglandin D₂ receptors, 224-26
 - radioligand-binding studies of,
 - 225-26
 - second messenger systems
 - for, 225
- Prostaglandin E receptors, 221-23
 - purification of, 223
 - radioligand-binding studies of,
 - 222-23
 - second messenger systems
 - for, 221-22
- Prostaglandin F_{2α} receptors,
 - 223-24
 - radioligand-binding studies of,
 - 224
 - second messenger systems
 - for, 224
- Prostaglandin H₂ receptors, 213-17
 - purification and biophysical
 - properties of, 217
 - radioligand-binding studies of,
 - 216-17
 - second messenger systems
 - for, 214-16
- Prostaglandins
 - derivation of, 123
- Protein kinase C
 - activation of
 - diacylglycerol and, 32, 76-77
 - long-term potentiation of synaptic transmission and,
 - 89
- Proteratogens, 167-75
- Protoporphyrin IX
 - benzodiazepine receptors and,
 - 313
- Psoralens
 - skin disease and, 59
- Psoriasis
 - anthralin and, 62
 - leukotrienes and, 123
 - topical glucocorticoids and,
 - 65-66
- Psychosis
 - glutamate receptors and, 460-61
- Pulsinellii, W. A., 406
- Putney, J. W. Jr., 79
- Pyrethrins
 - skin disease and, 59
- Q
- Quinidine
 - cytochrome P-450 enzymes
 - and, 247
- Quinn, G. P., 10
- Quinone oxidoreductases
 - embryonic defense and, 181-82
- Quirion, R., 41
- Quisqualate receptor
 - properties of, 375-76
 - synaptic transmission at, 376-77
- R
- Randerath, E., 426
- Randerath, K., 191
- Rasmussen, R. E., 195
- Rasmussen, T., 408
- Reddy, J. K., 147, 152
- Regan, J. D., 191
- Reid, W., 12
- Renin
 - release of
 - atriopectin and, 39
- Renshaw, R. R., 3
- Reserpine
 - ACTH hypersecretion and, 17
 - pituitary-adrenocortical system
 - and, 17
 - serotonin and, 12-13
- Reserpine syndrome
 - catecholamine depletion and,
 - 13
- Restriction fragment length
 - polymorphisms
 - kallikrein gene and, 347
- Retinitis pigmentosa
 - dialyzable leukocyte extract
 - therapy and, 497-98
- Retinoids
 - sebaceous gland function and,
 - 66
 - teratogenicity of, 166
- Reuter, P., 519
- Rhinovirus-14
 - structure of, 113
- Rhinoviruses
 - serotypes of, 113
- Rhodin, J., 146
- Richards, R. I., 344
- Rifampicin
 - S-mephenytoin 4-
 - hydroxylation and, 250
 - teratogenicity of, 175
- Rinkema, L. E., 130
- Robertson, R. P., 222
- Robinson, R. G., 408, 409
- Robson, C. N., 180
- Ronidazole
 - teratogenicity of, 171
- Rooney, T. A., 85
- Rossmann, M. G., 111
- Roth, B. L., 81
- Rothman, S. M., 388
- Rouiller, C., 146
- Russel, W. L., 199
- Ryan, P. B., 417
- S
- Saavedra, J. M., 41
- Salicylic acid
 - metabolism and distribution
 - of, 5
 - skin disease and, 59
- Salt appetite
 - atriopectin and, 42
- Sanders-Bush, E., 82
- Saper, C. B., 23
- Scala, R. A., 422
- Schaefer, H., 61, 64
- Schizophrenia
 - glutamate receptors and, 460-61
- Schoemaker, H., 312
- Scholtz, J. R., 59
- Schwartz, J.-C., 95
- Scopolamine
 - muscarinic cholinergic receptors and, 83
- Sebaceous glands
 - retinoids and, 66
- Second messengers
 - generation of
 - signal transduction at synapses and, 16
- Seizures
 - benzodiazepines and, 314
- Selenium
 - embryonic defense and, 181-82
- Septic shock
 - leukotrienes and, 123
- Serotonin
 - leukotrienes and, 126
 - reserpine and, 12-13

- Serotonergic receptors
 phosphoinositide turnover
 and, 81-83
- Serra, S. R., 354
- Setlow, R. B., 191
- Sexton, K., 417
- Shannon, J. A., 3-5
- Sherman, W. R., 96
- Sherry, S., 330
- Shimada, T., 248, 251
- Shimizu, T., 225
- Sick building syndrome, 429-30
- Single-chain urokinase-type plasminogen activator
 pharmacology of, 334
- Sladeczek, F., 87
- Slivka, A., 409
- Slott, V. L., 168
- Slow-reacting substance of anaphylaxis, 124
 bronchospastic properties of, 133
- Smith, H., 3
- Smith, W. L., 221
- Smooth endoplasmic reticulum
 drug-metabolizing enzyme system and, 9
- hepatic peroxisome proliferation and, 149
- Smooth muscle
 airway
 leukotrienes and, 125-27
- Snyder, D. W., 123, 127
- Snyder, J. S., 79
- Snyder, S. H., 307
- Sodium channel activators
 inositol phosphate release and, 92
- Soter, N. A., 134
- Stahl, M. L., 74
- Steele, M., 4
- Stewart, J. M., 350
- Stockmann, P. T., 23
- Stoughton, R. B., 55
- Stratum corneum
 percutaneous drug absorption and, 61-63
- Strauss, R. H., 517
- Streb, H., 77
- Streptokinase
 myocardial infarction and, 324
- pharmacology of, 329-31
- Stresemann, E., 133
- Stroke
 animal studies in, 403-12
- embolic, 410-11
- Substance P
 phosphoinositide hydrolysis and, 89
- Sulfinpyrazone
 biotransformation of phenylbutazone to, 11
- Sulfonamides
 dosage adjustments with, 4
- Sundt, T. M., 408
- Sung, C. Y., 523
- Superoxide dismutase
 embryonic defense and, 181-82
- Svoboda, D. J., 147
- Synapses
 signal transduction at
 second messenger generation and, 16
- T
- Tagliavia, A., 403
- Tamura, A., 408
- Tan, L., 253
- T cells
 interactive
 dialyzable leukocyte extract therapy and, 486-87
- Tennant, R., 324
- Teratogenesis
 chemical, 165-82
- Tesh, J. M., 174
- Testes
 benzodiazepine receptors in, 309-10
- Testosterone
 conversion to estrogens, 253
- cytochrome P-450 enzymes and, 247
- kallikrein gene expression and, 347-48
- teratogenicity of, 175
- Tetradotoxin
 inositol phosphate release and, 92
- Thalidomide
 teratogenicity of, 166, 172-74
- Theophylline
 leukotriene receptors and, 130
- Thermoregulation
 catecholamines and, 17
- Thiabendazole
 nail penetration by, 64
- skin disease and, 59
- Thiazide diuretics
 secondary dyslipidemias and, 266
- Thiols
 embryonic defense and, 181-82
- Thiopental
 clinical characteristics of
 tissue distribution and, 11
- metabolism and distribution of, 5
- Thomas, A. P., 78
- Thrombolysis
 myocardial infarction and, 323-36
- Thromboxane A₂ receptors, 213-17
 purification and biophysical properties of, 217
- radioligand-binding studies of, 216-17
- second messenger systems for, 214-16
- Thromboxanes
 derivation of, 123
- Thyrotropin-releasing hormone
 phosphoinositide hydrolysis and, 89
- Thyroxine
 dyslipidemias and, 281
- Tinea capitis
 antifungal therapy for, 66
- Tissue plasminogen activator
 fibrinolytic enzyme system and, 326-29
- pharmacology of, 332-34
- Tobacco smoke
 environmental, 422-27
- Tocopherols
 embryonic defense and, 181-82
- Tolunay, H. E., 23
- Tomato bushy stunt virus
 structure of, 113
- Transfer factor, 475-510
 characteristics of, 479
- immunotherapy with, 479-89
- mechanisms of action of, 505-8
- purification and characterization of, 508-9
- structure of, 502-5
- Transferrin
 embryonic defense and, 182
- Tremorine
 thermoregulation and, 17
- Triamcinolone acetonide
 biologic potency of
 vehicle and, 57
- Trichloroethylene
 hepatic peroxisome proliferation and, 147
- Tricyclic antidepressants
 serotonin and, 13
- 2,2,4-Trimethylpentane
 hepatic peroxisome proliferation and, 147
- Tuberculosis vulgaris
 dialyzable leukocyte extract therapy and, 492
- Tucker, S. S., 127
- U
- Udenfriend, S., 4, 5
- Undecylenic acid
 nail penetration by, 64

536 SUBJECT INDEX

- Uric acid
 - embryonic defense and, 181-82
- Urokinase
 - fibrinolytic enzyme system and, 326-29
 - myocardial infarction and, 324
 - pharmacology of, 332
- Uroporphyrin
 - benzodiazepine receptors and, 313
- V
 - Valproic acid
 - hepatic CoA and, 156
 - Varicella zoster
 - dialyzable leukocyte extract therapy and, 493
 - Vasoactive intestinal peptide
 - coexistence with acetylcholine, 95
 - Vasoconstrictor bioassay
 - glucocorticoid potency and, 56
 - Vasopressin
 - kallikrein gene expression and, 348
 - phosphoinositide hydrolysis and, 89
 - plasma atriopeptin levels and, 31
 - secretion of
 - atriopeptin and, 26, 41-42
 - Vavrek, R. J., 350
 - Veratridine
 - inositol phosphate release and, 92
 - Verma, A., 307
 - Very low-density lipoprotein
 - dysbetalipoproteinemia and, 266
 - Vessel, E. S., 1
 - Vickers, C. F. H., 62
 - Vickery, L. E., 253
 - Viral infections
 - dialyzable leukocyte extract therapy and, 493-96
 - Vitamin A acid
 - skin disease and, 59
 - Vitamin K
 - bile acid-binding resins and, 271
 - Volatile organic chemicals
 - toxic effects of, 429-33
- W
 - Wakade, C. G., 403
 - Walker, J. W., 82
 - Wallace, G. B., 3
 - Walters, K. A., 64
 - Watkins, J. C., 367, 386
 - Watts, J. W., 407
 - Way, E. L., 517
 - Weichman, B. M., 127
 - Weinberg, M. S., 355
 - Wells, P. G., 180
 - Welsch, F., 167
 - Westbrook, G. L., 372
 - White, P. C., 254
 - Wilhelm, O. G., 323
 - Williams, G. M., 189, 195
 - Williams, R. T., 10
 - Winsor, T., 64
 - Wroblewski, J. T., 441
- X
 - Xenobiotics
 - hepatomegaly and, 150
 - Xu, J., 93
- Y
 - Yang, B., 499
 - Yohimbine
 - inositol phosphate release and, 85
 - Yu, O.-F., 95
- Z
 - Zaun, H., 59
 - Zhu, X.-Z., 84
 - Zinc
 - N-methyl-D-aspartate receptors and, 445
 - Zubrod, G., 4, 5

